Under the agreement, Shire will obtain exclusive worldwide rights to ZFP Therapeutics designed to target four genes (for blood clotting Factors VII, VIII, IX and X) which will be used to investigate curative therapies for haemophilia A and B. Shire also receives the right to designate three additional gene targets.
Sangamo is responsible for all activities through filing of Investigational New Drug (IND) Applications and European Clinical Trial Applications (CTA) for each product and Shire will reimburse Sangamo for its internal and external research programme-related costs. Shire is responsible for clinical development and commercialisation of products emerging from the partnership.
Shire will pay Sangamo USD13m (EUR9.9m) upfront followed by research, regulatory, development and commercial milestone payments, and royalties on product sales.
(USD1 = EUR0.761)
Fosun Pharma agrees XH-S004 overseas licensing deal
Itepekimab meets primary endpoint in one of two Phase 3 COPD trials
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence